Register
Login:
Share:
Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis Watch Now

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Glaxosmithkline Share News (GSK)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Glaxosmithkline (GSK)


Share Price: 1,556.20Bid: 1,555.60Ask: 1,556.60Change: 1.20 (+0.08%)Riser - Glaxosmithkline
Spread: 1.00Spread as %: 0.06%Open: 1,554.00High: 1,556.20Low: 1,548.80Yesterday’s Close: 1,555.00




UK families face court fight over GSK diabetes drug

Wed, 30th Jan 2013 12:41

LONDON, Jan 30 (Reuters) - British families seeking compensation for damag
e caused by GlaxoSmithKline's now-withdrawn diabetes drug Avandia face a lengthy court battle, despite the company agreeing to settle similar U.S. cases.

Manchester-based law firm Express Solicitors said on Wednesday it had commenced high court proceedings in four cases against GSK over the way it developed and marketed Avandia.

The law firm, which has a further 15 cases on its books, said it believed it was the first to commence proceedings against the drugmaker over Avandia in British courts.

European authorities decided to pull Avandia from the market in September 2010 after it was linked to increased heart risks. It is still approved for a limited number of patients in the United States.

In the wake of the safety scandal, GSK paid hundreds of millions of dollars to settle litigation over Avandia in the United States.

In Britain, however, where the legal system has historically seen smaller compensation payments, it is planning a fight.

Express said GSK had indicated to the court it was ready to spend 600,000 pounds ($945,000) defending one of the cases, despite the fact the actual claim was worth a fraction of this amount.

'Even though a settlement was reached in the U.S. to settle lawsuits, it seems GSK wishes to put up a fight in the UK as indicated in correspondence pre-proceedings,' Express lawyer Daniel Slade said.

Avandia was first introduced into Britain in 2000 for people with type 2 diabetes who no longer responded adequately to older diabetes medicines. Express said many thousands of patients took the drug and many families could be eligible for compensation for death or harm caused to a relative.

'We have every sympathy for people with health complications associated with diabetes and those who care for them. Unfortunately, we are unable to comment on individual legal cases,' a GSK spokesman said.

'We continue to believe that the company acted appropriately and responsibly in its management of Avandia.'



(Reporting by Ben Hirschler; Editing by Dan Lalor) Keywords: GLAXOSMITHKLINE AVANDIA/BRITAIN

(ben.hirschler@thomsonreuters.com)(+44 20 7542 5082)(Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net)

COPYRIGHT
Copyright Thomson Reuters 2013. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.






Trade rhetoric weighs on European shares

(For a live blog on European stocks, type LIVE/ in an Eikon news window)May 17 (Reuters) - European shares dropped on Friday after three days of gains
[17 May '19 08:03]

Ex-divs to take 23.6 points off FTSE 100 on May 16

MILAN, May 13 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the lates
[13 May '19 09:55]

UK regulator investigates China's state broadcaster for airing TV confession

LONDON, May 8 (Reuters) - Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aire
[8 May '19 15:14]

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 (Reuters) - British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc i
[4 May '19 17:24]

UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study

(Adds background on market opportunity)May 2 (Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met
[2 May '19 18:41]

UPDATE 4-GSK sees shingles vaccine sales rising, as free cash flow concerns weigh

(Adds details on respiratory drugs performance)* Vaccines unit sales surge 20 percent, led by Shingrix* Shingrix sales to be "significantly" more than
[1 May '19 12:29]

UPDATE 2-Oil firms, exporters drag FTSE 100, while Sainsbury's, LSE outshine

* FTSE 100 down 0.4 pct* FTSE 250 down 0.1 pct* Oil majors, international firms weigh* Sainsbury's jumps on profit beat* Lloyds gains on hopes of more
[1 May '19 09:39]

UPDATE 2-Oil heavyweights, exporters guide FTSE 100 close to 7-month high

* FTSE 100 up 0.9 pct* FTSE 250 up 0.3 pct* Oil majors take main index higher* Oil price surge hits airlines* Softer sterling boosts exporter stocks*
[23 Apr '19 09:48]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.